Iradimed (IRMD) Gross Margin (2013 - 2026)

Iradimed (IRMD) has 14 years of Gross Margin data on file, last reported at 76.5% in Q1 2026.

• Gross Margin for Q1 2026 came in at 76.5%, up 43.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.84% (down 8.0% YoY), and the FY2025 annual result was 76.75%, down 19.0% from the prior year.
• Gross Margin improved to 76.5% in Q1 2026 per IRMD's latest filing, from 75.06% in the prior quarter.
• Over five years, Gross Margin peaked at 79.71% in Q2 2022 and troughed at 75.06% in Q4 2025.
• A 5-year average of 76.9% and a median of 76.5% in 2026 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2023: Gross Margin soared 497 bps in 2022, then tumbled 416 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 75.49% in 2022, then advanced by 2 bps to 76.86% in 2023, then slipped by 1 bps to 76.13% in 2024, then decreased by 1 bps to 75.06% in 2025, then rose by 2 bps to 76.5% in 2026.
• Business Quant data shows IRMD's Gross Margin at 76.5% in Q1 2026, 75.06% in Q4 2025, and 77.8% in Q3 2025.